Table V.
Rates of failure and relapses of spasmodic dysphonia after surgery and botulinum toxin injection.
| Author, Year | Treatment | Patients | Follow-up lenght | Relapses (%) | Post-surgical voice therapy | Relapses treatment |
|---|---|---|---|---|---|---|
| Aronson et al., 1983 75 | LNR | 33 | 36 months | 21 (63.64%) | n/a | Not reported |
| Berke et al., 1999 76 | SLAD-R | 21 | 36 months | 4 (19.05%) | n/a | 1/4 (25%) BTX, 1/4 (25%) collagen injection, 1/4 (25%) TMN, 1/4 voice therapy |
| Smith et al., 2000 77 | BTX-ona | 2 | 3-7 years | 2 (100%) | n/a | No further treatment |
| Galardi et al., 2001 78 | BTX-ona, BTX-abo | 15 | 3.53 years (1-8) | 12 (80%) pt had ³ 1 non effective injection | n/a | n/a |
| Park et al., 2003 79 | BTX-ona | 71 | 5 years | 6 (8.45%) | n/a | n/a |
| Isshiki et al., 2004 80 | TPII | 25 | 3-6 months | 1 (4.0%) | n/a | Revision TPII with TB (1/1, 100%) |
| Chhetri et al., 2006 81 | SLAD-R | 83 | 49 months | 12 (14.46%) | n/a | 5/12 (41.67%) BTX; 7/12 (58.33%) not reported |
| Cannito et al., 2008 82 | BTX-ona | 42 | 3-6 weeks | 7 (16.67%) all over 70 years of age | n/a | n/a |
| Sanuki et al., 2009 83 | TPII | 90 | 12-36 months | 7 (7.78%) | 1 | 2/7 (28.57%) removal of goretex or TB, no revision surgery; 5/7 (71.43%) new TB |
| Su et al., 2010 84 | TMN | 29 | 31 (12-63) months | 11 (37.93): 3 (10.34%) unsuccessful surgery | n/a | Revision TMN (7/8, 87.5%) |
| Sanuki et al., 2010 85 | TPII | 10 | 17.6 (7-25) months | 0 (0.0%) | n/a | - |
| Tsuji et al., 2012 86 | TMN | 15 | 31 (4-96) months | 2 (13.33%) | n/a | n/a |
| Nomoto et al., 2015 87 | TMN vs TPII | 65 (30 TMN, 35 TPII) | 6 months | 1 TMN (3.33%) | n/a | Revision TMN 1/1 (100%) |
| Schuering et al., 2020 88 | TMN | 22 | 30 months | 10 (45.45%) | n/a | TMN 10/10 (100%) |
| Zhao et al., 2020 89 | BTX-ona | 131 | n/a | 67 (12%) injections | n/a | n/a |
| Kohli et al., 2022 90 | BTX-inc | 9 | 2.56 months | 4 non responders | n/a | n/a |
TMN: thyroarytenoid myoneurectomy; TPII: thyroplasty type II; TB: titanium bridge; SLAD-R: selective laryngeal adductor denervation-reinnervation; LNR: laryngeal nerve resection; BTX-ona: onabotulinumtoxinA (Botox®); BTX-inc: incobotulinumtoxinA (Xeomin®, “naked” toxin with no surrounding proteins); BTX-abo: abobotulinumtoxinA (Dysport®).